Direct-to-Patient Survey Results Summary
Health Care, Innovation, Supply Chain
During the 2022 GCSG US conference in San Antonio, 65 attendees participated in our Direct-to-Patient (DtP) survey. While 2/3rd’s of the respondents represented pharmaceutical companies / sponsors, there is also a strong mix of input from service providers. Over 50% of participants also had experience with DtP. Though a need for technology improvements was noted, our industry’s adoption of patient centric services like DTP continues to boost the growth of decentralized trials.
Related Education Resources.
All ResourcesThe Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
GCSG 2024 US Conference Slides
Topic: Conference
Presentation
Members
